Daptomycin Hospira

RSS

daptomycin

Authorised
This medicine is authorised for use in the European Union.

Overview

Daptomycin Hospira is an antibiotic medicine used to treat the following bacterial infections in adults:

  • complicated infections of the skin and the ‘soft tissues’ below the skin. ‘Complicated’ means that the infection is difficult to treat, because it has spread to the deep tissues below the skin, because treatment with surgery might be needed, or because the patient has other conditions that might affect the treatment;
  • right-sided infective endocarditis (infection of the lining or the valves of the right side of the heart) caused by the bacterium Staphylococcus aureus (S. aureus). The decision to treat this infection with Daptomycin Hospira should be based on the likelihood that the medicine will work against the infection and on advice from an expert;
  • bacteraemia (infection of the blood) caused by S. aureus, associated with either of the two infections above.

Daptomycin Hospira contains the active substance daptomycin. It is a ‘generic medicine’. This means that Daptomycin Hospira contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the European Union (EU) called Cubicin.

This EPAR was last updated on 03/10/2019

Authorisation details

Product details
Name
Daptomycin Hospira
Agency product number
EMEA/H/C/004310
Active substance
daptomycin
International non-proprietary name (INN) or common name
daptomycin
Therapeutic area (MeSH)
  • Soft Tissue Infections
  • Skin Diseases, Bacterial
Anatomical therapeutic chemical (ATC) code
J01XX09
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Pfizer Europe MA EEIG
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
22/03/2017
Contact address

Boulevard de la Plaine 17
1050 Bruxelles
Belgium

Product information

09/04/2019 Daptomycin Hospira - EMEA/H/C/004310 - N/0010

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication

Daptomycin is indicated for the treatment of the following infections in adults (see sections 4.4 and 5.1):

  • Adult patients with complicated skin and soft-tissue infections (cSSTI).
  • Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice. (see sections 4.4 and 5.1).
  • Adult patients with Staphylococcus aureus bacteraemia (SAB) when associated with RIE or with cSSTI.

Daptomycin is active against Gram positive bacteria only (see section 5.1). In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Assessment history

How useful was this page?

Add your rating